News from NORD

NIH Workshop Focuses on Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis

Publish date: May 10, 2017

 

NIH recently hosted a workshop to bring researchers together to discuss severe drug reactions such as Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis and possible genetic factors that might predispose individuals to greater risk.

Recommended Reading

VIDEO: Pilot stem cell trial for multiple system atrophy shows promising results
MDedge Neurology
VIDEO: Big research trials at AAN bring up important cost decisions
MDedge Neurology
VIDEO: Cannabidiol reduces convulsive seizures in Dravet syndrome
MDedge Neurology
Cannabidiol cuts drop seizure frequency in Lennox-Gastaut syndrome
MDedge Neurology
VIDEO: About 1 in 20 ALS patients in Washington state chose assisted suicide
MDedge Neurology
FDA approves first new drug for ALS in decades
MDedge Neurology
PATH study: Subcutaneous immunoglobulin safe, effective for CIDP maintenance
MDedge Neurology
Patient Advocacy Groups Oppose AHCA
MDedge Neurology
NORD Issues RFPs for 2017 Research Grants for Study of Rare Diseases
MDedge Neurology
NORD Rare Action Network Issues Spring 2017 State Policy Legislative Tracker
MDedge Neurology